Sanofi (NASDAQ:SNY) Given Consensus Recommendation of "Hold" by Analysts

Sanofi (NASDAQ:SNY - Get Free Report) has received a consensus recommendation of "Hold" from the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $54.00.

SNY has been the topic of a number of research reports. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, March 19th. TD Cowen reiterated a "hold" rating on shares of Sanofi in a research note on Tuesday, December 30th. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Sanofi in a research note on Friday, January 16th. Citigroup reaffirmed a "neutral" rating on shares of Sanofi in a report on Monday, April 13th. Finally, Bank of America downgraded Sanofi from a "buy" rating to a "neutral" rating in a research report on Thursday, February 12th.

More Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Strong Q1 results: Sanofi beat consensus on both EPS and revenue (reported $2.18 EPS vs. $0.93 est.; revenue ~ $13.0B), driven by Dupixent and new launches, supporting an upbeat 2026 outlook. Sanofi's first-quarter earnings edges past estimates
• Positive Sentiment: U.S. approval expansion for Dupixent: FDA cleared Dupixent as the first biologic for young children (2–11) with uncontrolled chronic spontaneous urticaria — supports future addressable market and long-term growth of a core franchise. Dupixent approved in the US for young children with uncontrolled CSU
• Positive Sentiment: CHMP recommends Cenrifki (tolebrutinib) for EU approval to treat secondary progressive MS without relapses — regulatory progress that could broaden neurology portfolio. CHMP recommends Cenrifki (tolebrutinib)
• Positive Sentiment: Label expansion wins: FDA expanded Tzield for pediatric use, adding another growth pathway in specialty medicines. Tzield gets FDA nod for kids
• Neutral Sentiment: €2.3 billion bond offering priced across 2029/2033/2037 tranches — proceeds earmarked for general corporate purposes; modestly increases debt but at market rates given Sanofi’s low leverage. Sanofi prices €2.3 billion bond offering
• Negative Sentiment: Sarclisa SC BLA delayed: FDA set a new decision date (July 2026) after a filing delay — pushes potential commercialization timeline and may defer expected revenues from that subcutaneous formulation. Sarclisa SC BLA faces delay

Institutional Investors Weigh In On Sanofi

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CSM Advisors LLC bought a new stake in Sanofi during the 3rd quarter valued at approximately $18,244,000. Caprock Group LLC bought a new position in Sanofi in the 3rd quarter worth approximately $1,347,000. Natixis Advisors LLC grew its holdings in Sanofi by 11.8% during the 3rd quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company's stock valued at $146,952,000 after buying an additional 327,569 shares in the last quarter. Assetmark Inc. grew its holdings in Sanofi by 25.0% during the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company's stock valued at $16,859,000 after buying an additional 71,356 shares in the last quarter. Finally, Regal Partners Ltd raised its position in shares of Sanofi by 7.1% during the third quarter. Regal Partners Ltd now owns 1,657,539 shares of the company's stock valued at $78,236,000 after buying an additional 109,335 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Down 1.6%

Sanofi stock opened at $46.78 on Friday. The stock has a market cap of $114.10 billion, a PE ratio of 13.07, a price-to-earnings-growth ratio of 1.18 and a beta of 0.42. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. The stock has a fifty day moving average of $46.42 and a 200 day moving average of $47.98. Sanofi has a one year low of $43.32 and a one year high of $55.73.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be given a dividend of $2.4225 per share. This represents a dividend yield of 502.0%. The ex-dividend date of this dividend is Monday, May 4th. This is an increase from Sanofi's previous annual dividend of $2.04. Sanofi's payout ratio is presently 44.44%.

Sanofi Company Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.